Summit Showcase Seglin Technology at International Iminosugar Conference
(Thomson Reuters ONE) -
Summit Corporation plc
("Summit" or "the Company")
SUMMIT SHOWCASE SEGLIN TECHNOLOGY AT INTERNATIONAL IMINOSUGAR CONFERENCE
Oxford, UK, 29 June 2010, Summit Corporation plc (AIM: SUMM), announce that it
presented its Seglin(TM) technology platform at the international scientific
conference 'Iminosugars: Past, Present and Future' that was held at St John's
College, Oxford, UK on 28 June 2010.
The conference reviewed the latest scientific advancements in the area of
Iminosugars and included presentations from experts and key opinion leaders in
the field. As pioneers of second generation Iminosugars, or Seglins, Summit
showcased its innovative technology platform to an international audience from
industry and academia, and highlighted the potential of Seglin(TM) technology as
a source of new medicines to treat a range of major diseases.
Further information about the conference, including the full list of speakers,
is available at www.summitplc.com. In addition, the presentations given by
Summit are available on request from investors(at)summitplc.com
- END -
For more information, please contact:
Summit
Steven Lee, PhD
Richard Pye, PhD Tel: +44 (0)1235 443939
Singer Capital Markets (Nominated Adviser)
Shaun Dobson / Claes Spång Tel: +44 (0)20 3205 7500
Peckwater PR
Tarquin Edwards Tel: +44 (0)7879 458 364
tarquin.edwards(at)peckwaterpr.co.uk
About Summit
Summit is an Oxford, UK based drug discovery company with a portfolio of partner
funded drug programmes and an innovative technology platform called Seglins(TM)
for the discovery of new medicines.
Summit's partnered drug programmes require no further investment from the
Company but have contractual, success-based milestones potentially worth in
excess of $160 million and sales royalties rising to a low teen percentage.
Partners include leading orphan drug specialist BioMarin Pharmaceuticals
(Duchenne Muscular Dystrophy programme) and the Wellcome Trust (C. difficile
programme).
Seglin(TM) technology
Seglin(TM) technology is using new chemistry to access biological drug targets
that cannot be exploited by conventional drug discovery approaches. Summit's
internal research is currently focussed in the high value therapy areas of type
II diabetes and infectious diseases and the Company will further exploit the
technology's wider potential through strategic alliances.
Summit is listed on the AIM market of the London Stock Exchange and trades under
the ticker symbol SUMM. Further information is available at www.summitplc.com.
[HUG#1427625]
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Summit Corporation PLC via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 29.06.2010 - 10:00 Uhr
Sprache: Deutsch
News-ID 23157
Anzahl Zeichen: 0
contact information:
Town:
Abingdon,
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 234 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Summit Showcase Seglin Technology at International Iminosugar Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Summit Corporation PLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
